^
Association details:
| Biomarker: | HER-2 negative |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | AiRuiKa (camrelizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical study of camrelizumab combined with SOX in the adjuvant treatment of gastric adenocarcinoma or gastric esophageal junction adenocarcinoma
Excerpt:
...HER2 negative, voluntarily provide tumor tissue samples after surgery and adjuvant therapy; 10. ...
Trial ID:
Source:
Title:
Clinical Study of Camrelizumab Combined With SOX in the Adjuvant Treatment of Advanced Gastric Adenocarcinoma or Gastric Esophageal Junction Adenocarcinoma
Excerpt:
...HER2 negative, volunteering to provide tumor tissue samples after surgery and adjuvant therapy; 9....
Trial ID:
More C2 evidence
Source:
Title:
Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)
Excerpt:
...HER2 negative, MSS or pMMR. ...
Trial ID:
Source:
Title:
A single-arm, prospective, open-label clinical study of camrelizumab combined with the SOX regimen for first-line treatment of unresectable advanced or recurrent gastric cancer
Excerpt:
...Histological or cytologically confirmed diagnosis of previously untreated locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma; 3. ...
Trial ID:
Source:
Title:
Carrelizumab combined with XELOX in the treatment of stage IIIB/IIIC gastric cancer and gastroesophageal junction adenocarcinoma after D2 radical resection: a phase II clinical single-center, exploratory study
Excerpt:
...Her2 negative gastric adenocarcinoma/gastroesophageal junction adenocarcinoma confirmed by histology, no anti-tumor chemotherapy/immunotherapy has been performed in the past; 5. ...
Trial ID:
Less C2 evidence
Source:
Title:
1544P - Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment of advanced gastric/gastroesophageal junction cancer: A phase II clinical trial
Published date:
10/16/2023
Excerpt:
Camrelizumab plus albumin-bound paclitaxel and S-1 demonstrated promising activity and manageable safety in first-line treatment of HER-2- negative advanced gastric/gastroesophageal junction cancer.
Secondary therapy:
albumin-bound paclitaxel + gimeracil/oteracil/tegafur
Trial ID:
Source:
Title:
Camrelizumab combined with SOX in the first-line treatment of unresectable advanced or metastatic gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, prospective, and open-label clinical study.
Published date:
05/26/2022
Excerpt:
In this study (ChiCTR2000029691), eligible patients were diagnosed as unresectable advanced, postoperative recurrent ormetastatic, HER2-negative G/GEJ adenocarcinoma, and treatment-naive with chemotherapy, VEGFR2 inhibitors or PD-1/PD-L1 inhibitors. Patients received camrelizumab (200 mg, I.V., d1) and SOX regimen (oxaliplatin, 130 mg/m2, d1; S-1, 20mg/m2, bid, d1-14) every 3 weeks, until disease progression...with a median follow-up of 8.8 months (range, 0.9-16.8), safety and efficacy were assessed in 20 evaluable patients, with overall response of 8 partial response (PR) and 9 stable disease (SD). Confirmed ORR and DCR were 40.0% (95% CI, 20.0%-63.6%) and 85.0% (95% CI, 61.1%-96.0%), respectively. The median PFS and OS were 12.7 months (95% CI, 4.9-20.5) and 16.8 months (95% CI, 3.5-30.0), respectively.
Secondary therapy:
SOX
DOI:
10.1200/JCO.2022.40.16_suppl.e16090
Source:
Title:
Camrelizumab combined with chemotherapy followed by camrelizumab plus apatinib as first-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma
Published date:
03/25/2021
Excerpt:
Systemic treatment naïve patients with human epidermal growth factor receptor 2-negative advanced or metastatic G/GEJ adenocarcinoma received initial camrelizumab plus CAPOX for 4-6 cycles....The ORR was 58.3% (95% CI, 43.2-72.4) with this combination regimen. Median duration of response was 5.7 months (95% CI, 4.4-8.3). Median overall survival was 14.9 months (95% CI, 13.0-18.6), and median progression-free survival was 6.8 months (95% CI, 5.6-9.5), respectively...
Secondary therapy:
CAPOX
DOI:
10.1158/1078-0432.CCR-20-4691
Trial ID:
